trial

A Study in Schizophrenia Patients

NCTId NCT01086748
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 880 (estimated)
Sponsored by Eli Lilly and Company
Primary completion 2012-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
880 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-03
Primary completion
2012-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RisperidonePomaglumetad

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

28 total
Escondido, United StatesGarden Grove, United StatesParamount, United StatesWashington D.C., United StatesFort Lauderdale, United StatesHollywood, United StatesAtlanta, United StatesChicago, United StatesHoffman Estates, United StatesLake Charles, United StatesShreveport, United StatesFlowood, United States

Linked catalysts

1
A Study in Schizophrenia Patients — primary completion2012-05

Facts & assertions

4 sourced
Enrollment
880
Phase
PHASE2
Primary Completion Date
2012-05
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Pomaglumetad
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person